Sign In
Buy ONCT
$0.527
+0 (+0%)
At Close: Feb 28, 2025
Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results
08:05pm, Monday, 16'th Mar 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth qua
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
01:55pm, Sunday, 15'th Mar 2020
The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.Biogen Inc (NASDAQ: BIIB) was in the news for all wrong reasons, as an employee conferenc
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
12:00am, Sunday, 15'th Mar 2020
The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.
Biogen Inc (NASDAQ: BIIB) was in the news for all wrong...
Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update
08:08pm, Wednesday, 11'th Mar 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report its fourth quarter a
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an interim clinical data update for cirm
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
12th Annual Shamrock Shave - Food and Fun for the Whole Family
08:33pm, Monday, 10'th Feb 2020
One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
01:00pm, Thursday, 06'th Feb 2020
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of preclinical data fro
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of interim data from th
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has opened for enrollment a Phas
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of updated interim clin
We're Not Very Worried About Oncternal Therapeutics's (NASDAQ:ONCT) Cash Burn Rate
04:03pm, Friday, 20'th Sep 2019
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
08:01pm, Thursday, 08'th Aug 2019
SAN DIEGO, Aug. 08, 2019 -- Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen of cirmtuzumab + ibrutinib supports.
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib
12:00pm, Tuesday, 06'th Aug 2019
Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced
Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
08:01pm, Thursday, 01'st Aug 2019
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced
